Dr.ย Tonyย Mok
BMSc, MD, FRCPC, FRCP(Edin), FRCP(Lond), FHKCP, FHKAM(Medicine), FASCO
Chairman, Department of Clinical Oncology & Li Shu Fan Professor
corporate_fareThe Chinese University of Hong Kong, Hong Kong
Tony Mok
BMSc, MD, FRCPC, FRCP(Edin), FRCP(Lond), FHKCP, FHKAM(Medicine), FASCO
Prof. Tony S. K. Mok is one of Asia's foremost lung cancer specialists and a globally recognised authority in precision oncology. He serves as Chairman of the Department of Clinical Oncology and Li Shu Fan Professor of Clinical Oncology at The Chinese University of Hong Kong (CUHK).
Prof. Mok trained at the University of Alberta, Canada, completing his BMSc in 1982 and MD in 1984, followed by fellowship training in medical oncology at Princess Margaret Hospital in Toronto. After seven years as a community oncologist in Toronto, he returned to Hong Kong in 1996 to build a distinguished academic career at CUHK. He is internationally recognised for his leadership of the IPASS trial, which helped establish EGFR mutation-guided treatment as the modern standard for advanced lung cancer. He has contributed to approximately 340 peer-reviewed publications in journals including the New England Journal of Medicine, The Lancet, Science, Nature Medicine, and the Journal of Clinical Oncology. His work underpins NCCN, ASCO, ESMO and AMP/IASLC/CAP guidelines.
CancerFax can coordinate medical-report review and consultation support for international patients seeking an expert opinion from Prof. Tony Mok at CUHK.
Why Consider Prof. Tony Mok?
Prof. Mok is among the world's most cited lung cancer researchers and a pioneering force in EGFR-guided precision oncology. His trial leadership, guideline contributions and global academic network make him a uniquely authoritative choice for patients facing complex or advanced lung cancer decisions.
Areas of Specialisation
Biomarker-guided and molecularly targeted treatment for advanced lung cancer
Prof. Mok's practice focuses on precision-driven approaches to lung cancer, with particular depth in EGFR mutation-positive disease, ALK-positive lung cancer, acquired resistance mechanisms, and immunotherapy.
EGFR-Directed Precision Oncology
Expert-level management of EGFR-mutated non-small cell lung cancer across all treatment lines.
- arrow_rightFirst- and second-line EGFR TKI treatment planning for advanced NSCLC
- arrow_rightManagement of T790M-mediated resistance with third-generation inhibitors such as osimertinib
- arrow_rightSequencing decisions following first-line EGFR-directed therapy
- arrow_rightMolecular profiling and EGFR mutation testing to guide treatment choice
- arrow_rightPlasma-based circulating tumour DNA (cfDNA) testing for non-invasive diagnosis and monitoring
- arrow_rightBiomarker-driven treatment sequencing for advanced lung cancer
Molecular Targeted Therapy & Immunotherapy
Advanced systemic treatment approaches for oncogene-driven and immunotherapy-eligible lung cancers.
- arrow_rightFirst-line ALK-directed therapy planning including alectinib and crizotinib
- arrow_rightManagement of ALK-positive NSCLC based on clinical trial evidence, including ALEX and PROFILE 1014
- arrow_rightCheckpoint inhibitor therapy assessment for eligible NSCLC patients
- arrow_rightKEYNOTE-042 trial experience with pembrolizumab in PD-L1-positive advanced NSCLC
- arrow_rightIntegration of immunotherapy into multimodal lung cancer treatment planning
Procedures & Clinical Approaches
Precision treatment planning and advanced systemic therapy for lung cancer
Prof. Mok's clinical practice is centred on advanced systemic therapy, biomarker-guided treatment planning, and the application of clinical trial findings to individual patient management in lung cancer.
Precision Oncology & Targeted Therapy
Targeted TherapyMolecularly guided treatment planning for EGFR-mutated and ALK-positive lung cancers.
Medical Oncology for Advanced Lung Cancer
Medical OncologySystemic therapy planning for advanced and metastatic non-small cell lung cancer.
Second Opinion & Complex Case Review
Second OpinionExpert review for patients with advanced lung cancer, treatment resistance, or complex molecular profiles.
Monitoring & Disease Management
MonitoringOngoing disease assessment and response evaluation during and after systemic therapy.
Research & Publications
Landmark lung cancer trials and global guideline-defining research
Prof. Mok has contributed to approximately 340 peer-reviewed publications in leading international journals. His clinical trial leadership has defined the modern standard of care for EGFR-mutated and ALK-positive lung cancer globally.
Prof. Mok's publications and trial leadership have been adopted in NCCN, ASCO, ESMO and AMP/IASLC/CAP international lung cancer treatment guidelines.
Education & Training
Prof. Mok trained in Canada at the University of Alberta and completed speciality fellowship training in medical oncology at Princess Margaret Hospital, Toronto. He subsequently received fellowships from major Royal Colleges and Hong Kong medical academies.
Clinical Experience
Prof. Mok has spent nearly three decades in academic oncology at CUHK following seven years of community oncology practice in Toronto. He currently holds the most senior clinical and academic leadership positions in the Department of Clinical Oncology at CUHK.
How CancerFax Helps You Access Dr. Tony Mok
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Tony Mok's team โ with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history โ prepared as a structured clinical summary for Dr. Tony Mok's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Tony Mok before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Tony Mok's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Tony Mok's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Tony Mok's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Prof. Tony Mok
Prof. Mok specialises in lung cancer, with particular focus on non-small cell lung cancer (NSCLC), EGFR mutation-positive lung cancer, and ALK-positive lung cancer. He is one of the world's leading experts in biomarker-guided and molecularly targeted treatment for advanced lung cancer. CUHK also lists hepatocellular carcinoma as a research interest.
Prof. Mok was the principal investigator and first author of the landmark IPASS trial, which helped establish EGFR mutation testing as the defining step in treatment planning for advanced lung cancer. His research has been adopted by NCCN, ASCO, ESMO and AMP/IASLC/CAP international guidelines. He has contributed to approximately 340 peer-reviewed publications in journals including the New England Journal of Medicine, The Lancet and Nature Medicine.
Prof. Mok is based at The Chinese University of Hong Kong (CUHK), where he serves as Chairman of the Department of Clinical Oncology and Li Shu Fan Professor of Clinical Oncology. He also holds the role of Associate Dean (Translation and Entrepreneurship) at the Faculty of Medicine, CUHK.
CancerFax can coordinate medical-report review and consultation support for international patients seeking an expert opinion from Prof. Tony Mok at CUHK, subject to hospital availability and case acceptance. Please submit your medical reports through CancerFax and the team will guide you through the next steps.
A second-opinion request can be submitted through CancerFax with the patient's pathology reports, imaging, molecular test results and treatment history. CancerFax will prepare and coordinate the case for review by Prof. Mok's team, subject to availability. The consultation format will be confirmed by the institution.
Prof. Mok has extensive experience and research leadership in EGFR tyrosine kinase inhibitor therapy, management of T790M-mediated resistance with osimertinib, ALK inhibitor therapy including alectinib and crizotinib, and checkpoint immunotherapy in PD-L1-positive NSCLC. He also has research expertise in plasma circulating tumour DNA testing and novel targeted approaches.
Connect with Tony Mok Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.